Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 2/20 | 0.54 |
| ▸ | PLA2G2D | Q9UNK4 | 1/20 | 0.48 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | TRPM7 | Q96QT4 | 1/20 | 0.46 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8023186 | 0.99 | BACE1 (0.52) | BACE1PLA2G2DLTB4RSLC6A3TRPM7 | |
| SCHEMBL8011278 | 0.86 | BACE1 (0.55) | BACE1MAOBTSHR | |
| SCHEMBL8026218 | 0.85 | ALDH1A1 (0.43) | BACE1ALDH1A1CNR1CNR2TRPV1 | |
| SCHEMBL8009534 | 0.84 | BACE1 (0.53) | BACE1MAOBTRPV1TSHR | |
| SCHEMBL8019435 | 0.84 | BACE1 (0.58) | BACE1ALDH1A1MAOBTSHR | |
| SCHEMBL8010389 | 0.84 | BACE1 (0.53) | BACE1CNR2TRPV1 | |
| SCHEMBL8026637 | 0.83 | PPARG (0.47) | SLC6A3TRPM7DAGLAALDH1A1HPGD | |
| SCHEMBL12702676 | 0.83 | BACE1 (0.56) | BACE1ALDH1A1MAOBTRPV1TSHR | |
| SCHEMBL5590799 | 0.83 | BACE1 (0.56) | BACE1MAOBTSHR | |
| SCHEMBL8020241 | 0.83 | BACE1 (0.51) | BACE1CNR2TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110092591-A1 | PHENYL-PRENYL DERIVATIVES, OF MARINE AND SYNTHETIC ORIGIN, FOR THE TREATMENT OF COGNITIVE, NEURODEGENERATIVE OR NEURONAL DISEASES OR DISORDERS | NOSCIRA S.A. (ES) | 2011-04-21 | — | — | US | disclosed |
| WO-2009098287-A1 | PHENYL-PRENYL DERIVATIVES, OF MARINE AND SYNTHETIC ORIGIN, FOR THE TREATMENT OF COGNITIVE, NEURODEGENERATIVE OR NEURONAL DISEASES OR DISORDERS | NOSCIRA S.A. (ES) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092591-A1 | PHENYL-PRENYL DERIVATIVES, OF MARINE AND SYNTHETIC ORIGIN, FOR THE TREATMENT OF COGNITIVE, NEURODEGENERATIVE OR NEURONAL DISEASES OR DISORDERS | PSEN1, PARK7, APP | BACE1 8/4885PLA2G2D 270/4885LTB4R 1829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.